Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NEUROLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-02-14
DOI
10.1111/ene.13936
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis
- (2018) Johannes Lorscheider et al. Multiple Sclerosis Journal
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
- (2018) Mathias Granqvist et al. JAMA Neurology
- Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis
- (2018) Johannes Lorscheider et al. Multiple Sclerosis Journal
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
- (2016) Damiano Baroncini et al. Multiple Sclerosis Journal
- Rituximab in multiple sclerosis
- (2016) Jonatan Salzer et al. NEUROLOGY
- Comparative efficacy of fingolimod vs natalizumab
- (2016) Laetitia Barbin et al. NEUROLOGY
- Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
- (2016) Damiano Baroncini et al. Multiple Sclerosis Journal
- Brain health: time matters in multiple sclerosis
- (2016) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
- (2015) Tomas Kalincik et al. ANNALS OF NEUROLOGY
- Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
- (2015) L. Kappos et al. NEUROLOGY
- A changing treatment landscape for multiple sclerosis: challenges and opportunities
- (2014) F. Piehl JOURNAL OF INTERNAL MEDICINE
- A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort
- (2013) O. Outteryck et al. EUROPEAN JOURNAL OF NEUROLOGY
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
- (2012) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
- (2011) David B. Clifford ARCHIVES OF NEUROLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started